ARTICLE | Company News
BioLineRx, Santhera deal
October 18, 2010 7:00 AM UTC
Santhera granted BioLineRx exclusive rights to develop, sublicense and commercialize preclinical melanocortin 4 receptor (MC4R) antagonists, including lead compound SNT207979 and several follow-on co...